Russell Dambra, MD
Endocrinology, Diabetes & Metabolism · New Hyde Park, NYNPI 1154381929
Payments from drug & device makers
Across 147 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$303
- Novo Nordisk$291
- Xeris Pharmaceuticals, Inc.$213
- Lilly USA, LLC$202
- Sanofi-aventis U.S. LLC$173
- AbbVie$171
- plus $2K from 30 others
What the payments were for
- Food & beverage$2,84798%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 16 | $303 |
| Novo Nordisk | 15 | $291 |
| Xeris Pharmaceuticals, Inc. | 10 | $213 |
| Lilly USA, LLC | 8 | $202 |
| Sanofi-aventis U.S. LLC | 8 | $173 |
| AbbVie | 9 | $171 |
| AstraZeneca(2 entities) | 9 | $159 |
| Radius Health, Inc. | 5 | $133 |
| Mannkind Corporation | 6 | $112 |
| Kowa Pharmaceuticals America, Inc. | 5 | $84 |
| Novartis | 4 | $82 |
| Abbott | 4 | $79 |
| Corcept Therapeutics | 3 | $77 |
| Amarin Pharma, Inc. | 4 | $75 |
| IBSA Pharma Inc. | 3 | $72 |
| Antares Pharma, Inc. | 4 | $70 |
| Medtronic(2 entities) | 4 | $66 |
| Merck | 4 | $63 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Amneal Pharmaceuticals LLC | 2 | $45 |
| Boehringer Ingelheim | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $41 |
| Avvisto Therapeutics, LLC | 2 | $36 |
| Ipsen Biopharmaceuticals, Inc | 2 | $26 |
| Chiesi USA, Inc. | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Valeritas, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Lifescan, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Averitas Pharma Inc. | 1 | $14 |
| Insulet Corporation | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,892 in reported general payments places this provider in the 60th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 153 | $309,840 |
| MounjaroTirzepatide | 84 | $142,348 |
| JanuviaSitagliptin Phosphate | 106 | $125,616 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 46 | $82,934 |
| ProliaDenosumab | 26 | $45,510 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $32,772 |
| TrulicityDulaglutide | 18 | $30,229 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $27,435 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $25,976 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $22,394 |
| SynthroidLevothyroxine Sodium | 350 | $22,373 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $21,951 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $19,981 |
| TradjentaLinagliptin | 20 | $19,904 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 20 | $19,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $291 | $309,840153 claims |
| MerckJanuvia, Janumet, Janumet Xr | $63 | $185,824155 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $202 | $180,060124 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog | $173 | $89,42357 claims |
| AmgenProlia | $303 | $45,51026 claims |
| AbbVieSynthroid | $171 | $22,373350 claims |
| Boehringer IngelheimTradjenta | $43 | $19,90420 claims |
| Antares Pharma, Inc.Xyosted | $70 | $13,69719 claims |
| IBSA Pharma Inc.Tirosint | $72 | $7,32219 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $6,909373 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New Hyde Park
- Kenneth HershonNew Hyde Park$1.9M
- Isaac SachmechiNew Hyde Park$927K
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Michael ShanikSmithtown$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.